Register Login

Supernus Pharmaceuticals Inc (SUPN)

Director Khattar Jack A. 🟡 adjusted position in 34.8K shares (2 derivative) of SUPERNUS PHARMACEUTICALS, INC. (SUPN) at $45.12 ($3.0M) Transaction Date: Aug 27, 2025 | Filing ID: 000010

Full text
Register to leave comments
  • News bot Aug. 29, 2025, 8:06 p.m.

    🔍 Khattar Jack A. (Director)

    Company: SUPERNUS PHARMACEUTICALS, INC. (SUPN)

    Report Date: 2025-08-27

    Transaction Summary:

    • Total transactions: 7
    • Derivative instruments: 2
    • Holdings reported: 1
    • Total shares acquired: 55,974
    • Total shares sold: 90,774
    • Total shares held: 1,005,600

    Detailed Transactions and Holdings:

    • Acquired 17,195 shares of Common Stock at $12.98 per share (Direct)
      Date: 2025-08-27 | Code: M | equity_swap_involved: 0 | shares_owned_after: 1,088,654.00 | transaction_form_type: 4 | Footnotes: F1
    • Sold 10,650 shares of Common Stock at $45.05 per share (Direct)
      Date: 2025-08-27 | Code: S | equity_swap_involved: 0 | shares_owned_after: 1,078,004.00 | transaction_form_type: 4 | Footnotes: F2
    • Acquired 38,779 shares of Common Stock at $12.98 per share (Direct)
      Date: 2025-08-28 | Code: M | equity_swap_involved: 0 | shares_owned_after: 1,116,783.00 | transaction_form_type: 4 | Footnotes: F1
    • Sold 24,150 shares of Common Stock at $45.12 per share (Direct)
      Date: 2025-08-28 | Code: S | equity_swap_involved: 0 | shares_owned_after: 1,092,633.00 | transaction_form_type: 4 | Footnotes: F3
    • Holds 0 shares of Common Stock (Direct)
      Date: 2025-08-27 | Code: H | nature_of_ownership: By the KBT Trust | shares_owned_after: 1,005,600.00
    • Sold 17,195 shares of Employee Stock Option (Right to Buy) at $12.98 per share (Derivative)
      Date: 2025-08-27 | Code: M | Expires: 2026-03-01 | Exercise: 2017-03-01 | equity_swap_involved: 0 | shares_owned_after: 113,779.00 | transaction_form_type: 4 | Footnotes: F4
    • Sold 38,779 shares of Employee Stock Option (Right to Buy) at $12.98 per share (Derivative)
      Date: 2025-08-28 | Code: M | Expires: 2026-03-01 | Exercise: 2017-03-01 | equity_swap_involved: 0 | shares_owned_after: 75,000.00 | transaction_form_type: 4 | Footnotes: F4

    Footnotes:

    • F1: Transaction made pursuant to a 10b5-1 trading plan adopted November 14, 2024.
    • F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.10. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
    • F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.26. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
    • F4: The option vested in four equal installments beginning on March 1, 2017.

Search

News categories